CDER's Generational Shift Brings New Reviewers With Little Experience
This article was originally published in The Tan Sheet
The past two fiscal years have seen great gains in the number of new employees hired in FDA's Center for Drug Evaluation and Research, but the result is a relatively under-experienced staff: 38 percent of employees in both CDER and the Office of New Drugs have less than two years of on-the-job experience
You may also be interested in...
Approximately 200 employees in FDA's Center for Drug Evaluation and Research are exiled from the agency’s White Oak campus for the next few years due to overcrowding.
Office of New Drugs Director John Jenkins sees a possible side benefit for FDA of more efficient drug approval processes should the agency's transparency initiative lead to the public release of "complete response" letters
After an almost two-year hiatus from strict adherence to Prescription Drugs User Fee Act review timeframes, Office of New Drugs Director John Jenkins has told review staff that, once again, they should strive to meet the user fee deadlines